{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:49Z","timestamp":1787021089023,"version":"build-2736575974"},"reference-count":42,"publisher":"Royal College of Psychiatrists","issue":"2","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2024,3]]},"abstract":"\n Background<\/jats:title>\n Cannabis-based medicinal products (CBMPs) are increasingly being used to treat post-traumatic stress disorder (PTSD), despite limited evidence of their efficacy. PTSD is often comorbid with major depression, and little is known about whether comorbid depression alters the effectiveness of CBMPs.<\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n To document the prevalence of depression among individuals seeking CBMPs to treat PTSD and to examine whether the effectiveness of CBMPs varies by depression status.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n Data were available for 238 people with PTSD seeking CBMP treatment (5.9% of the treatment-seeking sample) and 3-month follow-up data were available for 116 of these. Self-reported PTSD symptoms were assessed at treatment entry and at 3-month follow-up using the PTSD Checklist \u2013 Civilian Version (PCL-C). The probable presence of comorbid depression at treatment entry was assessed using the nine-item Patient Health Questionnaire (PHQ-9). Additional data included sociodemographic characteristics and self-reported quality of life.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In total, 77% met screening criteria for depression, which was associated with higher levels of PTSD symptomatology (mean 67.8\n v.<\/jats:italic>\n 48.4,\n F<\/jats:italic>\n (1,236)<\/jats:sub>\n = 118.5,\n P<\/jats:italic>\n < 0.001) and poorer general health, quality of life and sleep. PTSD symptomatology reduced substantially 3 months after commencing treatment (mean 58.0\n v.<\/jats:italic>\n 47.0,\n F<\/jats:italic>\n (1,112)<\/jats:sub>\n = 14.5,\n P<\/jats:italic>\n < 0.001), with a significant interaction (\n F<\/jats:italic>\n (1,112)<\/jats:sub>\n = 6.2,\n P<\/jats:italic>\n < 0.05) indicating greater improvement in those with depression (mean difference 15.3) than in those without (mean difference 7).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Depression is common among individuals seeking CBMPs to treat PTSD and is associated with greater symptom severity and poorer quality of life. Effectiveness of CBMPs for treating PTSD does not appear to be impaired in people with comorbid depression.<\/jats:p>\n <\/jats:sec>","DOI":"10.1192\/bjo.2024.13","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T01:38:46Z","timestamp":1710207526000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":11,"title":["Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence"],"prefix":"10.1192","volume":"10","author":[{"given":"Michael T.","family":"Lynskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkyoni","family":"Athanasiou-Fragkouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7714-3446","authenticated-orcid":false,"given":"Hannah","family":"Thurgur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Katrin","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"S2056472424000139_ref4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00213-021-06047-8","article-title":"Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada","volume":"239","author":"Leung","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"S2056472424000139_ref22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brat.2016.10.006","article-title":"Exclusion of participants based on substance use status: findings from randomized controlled trials of treatments for PTSD","volume":"89","author":"Leeman","year":"2017","journal-title":"Behav Res Ther"},{"key":"S2056472424000139_ref25","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00213-021-05855-2","article-title":"Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from project Twenty21","volume":"239","author":"Sakal","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"S2056472424000139_ref9","doi-asserted-by":"crossref","first-page":"108216","DOI":"10.1016\/j.pharmthera.2022.108216","article-title":"Cannabinoids and the endocannabinoid system in fibromyalgia: a review of preclinical and clinical research","volume":"240","author":"Bourke","year":"2022","journal-title":"Pharmacol Ther"},{"key":"S2056472424000139_ref14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"S2056472424000139_ref19","doi-asserted-by":"crossref","first-page":"1014630","DOI":"10.3389\/fpsyt.2022.1014630","article-title":"Medical cannabis for treatment-resistant combat PTSD","volume":"13","author":"Nacasch","year":"2022","journal-title":"Front Psychiatry"},{"key":"S2056472424000139_ref36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31887\/DCNS.2015.17.2\/jflory","article-title":"Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations","volume":"17","author":"Flory","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"key":"S2056472424000139_ref6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/dar.13116","article-title":"Trends in medical cannabis licensure, Israel, 2013\u20132018","volume":"39","author":"Sznitman","year":"2020","journal-title":"Drug Alcohol Rev"},{"key":"S2056472424000139_ref3","doi-asserted-by":"crossref","first-page":"101612","DOI":"10.1016\/j.ctcp.2022.101612","article-title":"Characterizing anxiety, pain, sleep, and quality of life among patients in a state medical marijuana program","volume":"48","author":"Ashare","year":"2022","journal-title":"Complement Ther Clin Pract"},{"key":"S2056472424000139_ref5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s42238-020-00038-w","article-title":"Medical cannabis use in the United States: a retrospective database study","volume":"2","author":"Mahabir","year":"2020","journal-title":"J Cannabis Res"},{"key":"S2056472424000139_ref32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"S2056472424000139_ref17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14737175.2022.2155139","article-title":"Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK medical Cannabis registry","volume":"22","author":"Pillai","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"S2056472424000139_ref27","unstructured":"27 EuroQol Research Foundation. EQ-5D-5L User Guide. EuroQol, 2019."},{"key":"S2056472424000139_ref8","first-page":"230","article-title":"Potential utility of cannabidiol in stress-related disorders","volume":"8","author":"Lookfong","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"S2056472424000139_ref12","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J Biol Chem"},{"key":"S2056472424000139_ref40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1208\/s12248-021-00616-7","article-title":"Cannabinoid interactions with cytochrome P450 drug metabolism: a full-Spectrum characterization","volume":"23","author":"Doohan","year":"2021","journal-title":"AAPS J"},{"key":"S2056472424000139_ref18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.brat.2003.07.010","article-title":"Psychometric properties of the impact of event scale - revised","volume":"41","author":"Creamer","year":"2003","journal-title":"Behav Res Ther"},{"key":"S2056472424000139_ref2","doi-asserted-by":"crossref","first-page":"891498","DOI":"10.3389\/fpain.2022.891498","article-title":"Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: evidence from Project Twenty 21","volume":"3","author":"Schlag","year":"2022","journal-title":"Front Pain Res Lausanne"},{"key":"S2056472424000139_ref24","first-page":"22","article-title":"Comorbidity of psychiatric disorders and posttraumatic stress disorder","volume":"61","author":"Brady","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"S2056472424000139_ref23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000499917","article-title":"Have treatment studies of depression become even less generalizable? Applying the inclusion and exclusion criteria in placebo-controlled antidepressant efficacy trials published over 20 years to a clinical sample","volume":"88","author":"Zimmerman","year":"2019","journal-title":"Psychother Psychosom"},{"key":"S2056472424000139_ref11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"S2056472424000139_ref1","doi-asserted-by":"crossref","first-page":"20503245231167373","DOI":"10.1177\/20503245231167373","article-title":"Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: real-world evidence from project Twenty21","volume":"9","author":"Lynskey","year":"2023","journal-title":"Drug Sci Policy Law"},{"key":"S2056472424000139_ref26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"S2056472424000139_ref29","volume-title":"IBM SPSS Statistics for Windows, Version 29.0","year":"2022"},{"key":"S2056472424000139_ref33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1037\/a0031523","article-title":"The relationship between posttraumatic and depressive symptoms during prolonged exposure with and without cognitive restructuring for the treatment of posttraumatic stress disorder","volume":"81","author":"Aderka","year":"2013","journal-title":"J Consult Clin Psychol"},{"key":"S2056472424000139_ref37","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"S2056472424000139_ref41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and cytochrome P450 interactions","volume":"17","author":"Zendulka","year":"2016","journal-title":"Curr Drug Metab"},{"key":"S2056472424000139_ref42","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/bcp.15841","article-title":"Bayesian analysis of real-world data as evidence for drug approval: remembering Sir Michael Rawlins","volume":"89","author":"Szigeti","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"S2056472424000139_ref20","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.pctr.0010009","article-title":"Factors that can affect the external validity of randomised controlled trials","volume":"1","author":"Rothwell","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"S2056472424000139_ref34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1037\/a0030485","article-title":"Changes in posttraumatic stress disorder and depressive symptoms during cognitive processing therapy: evidence for concurrent change","volume":"80","author":"Liverant","year":"2012","journal-title":"J Consult Clin Psychol"},{"key":"S2056472424000139_ref7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1515\/jbcpp-2020-0279","article-title":"Use of cannabinoids for the treatment of patients with post-traumatic stress disorder","volume":"33","author":"Forsythe","year":"2021","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"S2056472424000139_ref31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.beth.2020.04.015","article-title":"The effect of concurrent depression on PTSD outcomes in trauma-focused psychotherapy: a meta-analysis of randomized controlled trials","volume":"52","author":"Kline","year":"2021","journal-title":"Behav Ther"},{"key":"S2056472424000139_ref15","doi-asserted-by":"crossref","first-page":"e0246990","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial","volume":"16","author":"Bonn-Miller","year":"2021","journal-title":"PLoS One"},{"key":"S2056472424000139_ref30","doi-asserted-by":"crossref","first-page":"e2312522","DOI":"10.1001\/jamanetworkopen.2023.12522","article-title":"Assessment of medical cannabis and health-related quality of life","volume":"6","author":"Arkell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"S2056472424000139_ref10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/NSS.S390583","article-title":"Medical cannabis use patterns for sleep disorders in Australia: results of the cross-sectional CAMS-20 survey","volume":"15","author":"Suraev","year":"2023","journal-title":"Nat Sci Sleep"},{"key":"S2056472424000139_ref28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"S2056472424000139_ref35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14737175.2022.2161894","article-title":"Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry","volume":"22","author":"Mangoo","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"S2056472424000139_ref38","doi-asserted-by":"crossref","DOI":"10.1089\/can.2023.0052","article-title":"Does the \u2018entourage effect\u2019 in cannabinoids exist? A narrative scoping review","author":"Simei","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"S2056472424000139_ref16","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jclp.21845","article-title":"The PTSD Checklist-Civilian Version: reliability, validity, and factor structure in a nonclinical sample","volume":"68","author":"Conybeare","year":"2012","journal-title":"J Clin Psychol"},{"key":"S2056472424000139_ref13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"S2056472424000139_ref21","doi-asserted-by":"crossref","first-page":"1027159","DOI":"10.3389\/fpsyt.2022.1027159","article-title":"The value of real world evidence: the case of medical cannabis","volume":"13","author":"Schlag","year":"2022","journal-title":"Front Psychiatry"},{"key":"S2056472424000139_ref39","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1055481","article-title":"Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions","volume":"13","author":"Smith","year":"2023","journal-title":"Front Psychiatry"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472424000139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T01:39:05Z","timestamp":1710207545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472424000139\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["S2056472424000139"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2024.13","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Copyright \u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e62"}}